284 related articles for article (PubMed ID: 19941044)
1. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.
Yuen E; Gueorguieva I; Wise S; Soon D; Aarons L
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):3-24. PubMed ID: 19941044
[TBL] [Abstract][Full Text] [Related]
2. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population.
Lee SC; Ng SS; Oldenburg J; Chong PY; Rost S; Guo JY; Yap HL; Rankin SC; Khor HB; Yeo TC; Ng KS; Soong R; Goh BC
Clin Pharmacol Ther; 2006 Mar; 79(3):197-205. PubMed ID: 16513444
[TBL] [Abstract][Full Text] [Related]
3. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
Lu Y; Yang J; Zhang H; Yang J
Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
[TBL] [Abstract][Full Text] [Related]
4. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
[TBL] [Abstract][Full Text] [Related]
5. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.
Gan GG; Phipps ME; Lee MM; Lu LS; Subramaniam RY; Bee PC; Chang SH
Ann Hematol; 2011 Jun; 90(6):635-41. PubMed ID: 21110192
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin.
Sangviroon A; Panomvana D; Tassaneeyakul W; Namchaisiri J
Drug Metab Pharmacokinet; 2010; 25(6):531-8. PubMed ID: 20930419
[TBL] [Abstract][Full Text] [Related]
7. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
8. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.
Veenstra DL; You JH; Rieder MJ; Farin FM; Wilkerson HW; Blough DK; Cheng G; Rettie AE
Pharmacogenet Genomics; 2005 Oct; 15(10):687-91. PubMed ID: 16141794
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
[TBL] [Abstract][Full Text] [Related]
11. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
12. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
[TBL] [Abstract][Full Text] [Related]
13. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
14. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
15. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
[TBL] [Abstract][Full Text] [Related]
16. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
17. [Gene polymorphism of CYP450 2C9 and VKORC1 in Chinese population and their relationships to the maintaining dosage of warfarin].
Zhang YN; Cui W; Han M; Zheng B; Liu F; Xie RQ; Yang XH; Gu GQ; Zheng HM; Wen JK
Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Feb; 31(2):218-22. PubMed ID: 21215088
[TBL] [Abstract][Full Text] [Related]
18. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.
Verstuyft C; Delavenne X; Rousseau A; Robert A; Tod M; Diquet B; Lebot M; Jaillon P; Becquemont L
Clin Pharmacokinet; 2012 Jan; 51(1):41-53. PubMed ID: 22149257
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
